We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rocket Pharmaceuticals Inc | NASDAQ:RCKT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 22.83 | 18.00 | 23.40 | 35 | 09:01:17 |
By Sabela Ojea
Shares of Rocket Pharmaceuticals surged 34% to $20.46 in post-market trading on Tuesday after the company said it reached alignment with the Food and Drug Administration regarding its Phase 2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study would evaluate the use of the investigational gene therapy RP-A501 to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known for weakening the heart and movement muscles, as well as intellectual disability.
The trial will support accelerated approval of Rocket's treatment by the FDA.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:13 ET (21:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Rocket Pharmaceuticals Chart |
1 Month Rocket Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions